Compare Biogen Inc (BIIB) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Funko Inc — how do they compare? Biogen Inc trades at $192.49 (market cap $28.34B), while Funko Inc trades at $5.62 (market cap $310.19M). The key difference: Biogen Inc is far larger — about 91.4× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | FNKO | |
|---|---|---|
Market Cap | $28.34B | $310.19M |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $5.88 |
52-Week Low | $122.68 | $2.46 |
Enterprise Value | $30.62B | $555.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
FNKO trades at $5.69, up 1.97% with a bullish technical signal. Recent earnings beat expectations, yet the company reported a net loss of $67.36M in 2025. Revenue declined to $908.21M, but Q1 2026 showed improvement. Analyst consensus is mixed with 42.86% buy ratings. Cash flow trends are stabilizing, though negative profitability and high debt remain concerns.
Outlook hinges on execution of new product launches and cost management. Opportunities include brand strength and collectibles demand, but risks involve sustained losses, competitive pressure, and leverage. The stock presents a speculative growth play with significant turnaround requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
